Adverum Biotechnologies Inc Asset Resilience Ratio
Adverum Biotechnologies Inc asset resilience ratio. Adverum Biotechnologies Inc (ADVM) has an Asset Resilience Ratio of 0.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Adverum Biotechnologies Inc (ADVM) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Adverum Biotechnologies Inc (2014–2024)
Asset resilience ratio of Adverum Biotechnologies Inc from 2014 to 2024. This chart shows how Adverum Biotechnologies Inc's Asset Resilience Ratio has changed over time. Read Adverum Biotechnologies Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Adverum Biotechnologies Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Adverum Biotechnologies Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Adverum Biotechnologies Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Adverum Biotechnologies Inc Industry Peers by Asset Resilience Ratio
Compare Adverum Biotechnologies Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Adverum Biotechnologies Inc Asset Resilience Ratio by Year (2014–2024)
Adverum Biotechnologies Inc asset resilience ratio by year from 2014 to 2024. The table below shows the annual Asset Resilience Ratio data for Adverum Biotechnologies Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 36.16% | $65.04 Million | $179.84 Million | +22.35pp |
| 2023-12-31 | 13.82% | $21.53 Million | $155.77 Million | -24.17pp |
| 2022-12-31 | 37.99% | $117.16 Million | $308.37 Million | -23.64pp |
| 2021-12-31 | 61.63% | $270.99 Million | $439.73 Million | -14.49pp |
| 2020-12-31 | 76.11% | $367.31 Million | $482.57 Million | +31.15pp |
| 2019-12-31 | 44.96% | $100.14 Million | $222.73 Million | +21.48pp |
| 2018-12-31 | 23.48% | $50.13 Million | $213.50 Million | -35.94pp |
| 2017-12-31 | 59.42% | $119.97 Million | $201.91 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $234.58 Million | -- |
| 2015-12-31 | 14.28% | $37.73 Million | $264.32 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $161.91 Million | -- |
About Adverum Biotechnologies Inc
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is … Read more